Efficacy of Eplerenone monotherapy and Valsartan monotherapy on patients of Subclinical Cushing's syndrome with hypertension and non-functioning adrenocortical adenoma with hypertension. Efficacy of Eplerenone monotherapy and Valsartanmonotherapy on patients of Subclinical Cushing's syn ...
Efficacy of Eplerenone monotherapy and Valsartan monotherapy on patients of Subclinical Cushing's syndrome with hypertension and non-functioning adrenocortical adenoma with hypertension. - A pilot study to compare efficacy of Eplerenone monotherapy with Valsartan monotherapy. Efficacy of Eplerenone monotherapy and Valsartanmonotherapy on patients of Subclinical Cushing's syn ...
Subclinical Cushing's syndrome with hypertension and non-functioning adrenocortical adenoma with hypertension. Subclinical Cushing's syndrome with hypertension and non-functioning adrenocortical adenoma with hyp ...
50mg of Eplerenone monotherapy once daily for 6 weeks on subclinical Cushing's syndrome 80mg of Valsartan monotherapy once daily for 6 weeks on subclinical Cushing's syndrome 50mg of Eplerenone monotherapy once daily for 6 weeks on non-functioning adrenocortical adenoma 80mg of Valsartan monotherapy once daily for 6 weeks on non-functioning adrenocortical adenoma 50mg of Eplerenonemonotherapy once daily for 6 weeks on subclinical Cushing's syndrome 80mg of Valsar ...
Hiroshima University HospitalDepartment of Endocrinology and Diabetes mellitus